We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+1.89%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$50M
AUM Growth
-$5.68M
Cap. Flow
+$9.56M
Cap. Flow %
19.14%
Top 10 Hldgs %
97.9%
Holding
20
New
3
Increased
2
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
TYME
Tyme Technologies, Inc. Common Stock
TYME
+$12.1M
2
GSK icon
GSK
GSK
+$2.03M
3
ASRT
Assertio
ASRT
+$1.18M
4
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$401K

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$3.65M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 83.31%
2 Miscellaneous 16.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYME
1
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
$11M 21.92%
+2,075,000
New +$12.1M
PFE icon
2
Pfizer
PFE
$160B
$8.93M 17.86%
263,500
– –
NVLN
3
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.2M 12.4%
881,440
+50,000
+6% +$401K
GILD icon
4
Gilead Sciences
GILD
$185B
$6.08M 12.16%
75,000
– –
GILD icon
5
CALL
Gilead Sciences
GILD
$185B
$4.86M 9.73%
60,000
– –
ASRT
6
DELISTED
Assertio
ASRT
$4.05M 8.11%
11,667
+2,500
+27% +$1.18M
ASRT
7
PUT
DELISTED
Assertio
ASRT
$2.43M 4.87%
+7,000
New +$3.3M
GSK icon
8
GSK
GSK
$101B
$2.03M 4.06%
+40,000
New +$2.03M
LAB icon
9
Standard BioTools
LAB
$253M
$1.82M 3.64%
360,500
– –
AMRN
10
Amarin Corp
AMRN
$299M
$1.57M 3.15%
22,500
– –
BIS icon
11
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$514K 1.03%
3,125
– –
LAB icon
12
CALL
Standard BioTools
LAB
$253M
$504K 1.01%
100,000
-50,000
-33% -$210K
FCSC
13
CALL
DELISTED
Fibrocell Science Inc.
FCSC
$31K 0.06%
2,000
– –
AORT icon
14
PUT
Artivion
AORT
$1.3B
– –
-200,000
Closed -$3.99M
ASRT
15
CALL
DELISTED
Assertio
ASRT
– –
-1,667
Closed -$1.07M
BIS icon
16
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
– –
-25,000
Closed -$4.85M
TEVA icon
17
Teva Pharmaceuticals
TEVA
$43.8B
– –
-75,000
Closed -$2.49M
VIXY icon
18
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
– –
-781
Closed -$2.66M
IMMU
19
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-100,000
Closed -$883K
AGN
20
DELISTED
Allergan plc
AGN
– –
-15,000
Closed -$3.65M

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Healthcare Value Capital held 20 positions worth $50M, down 10% from $55.7M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Healthcare Value Capital deployed $9.56M of net new capital in Q3 2017, opening 3 new positions and adding to 2 existing holdings. Its largest new stake was Tyme Technologies, Inc. Common Stock: 2,075,000 shares worth $11M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

On the sell side, the most notable exit was Allergan plc, an estimated $3.65M sold.

  • Healthcare Value Capital's largest Q3 2017 buy was Tyme Technologies, Inc. Common Stock: 2,075,000 shares worth $11M.
  • Healthcare Value Capital added most to Assertio in Q3 2017, an estimated $1.18M increase.
  • Healthcare Value Capital fully exited Allergan plc in Q3 2017, selling an estimated $3.65M.
  • Healthcare Value Capital's ten largest holdings make up 98% of its $50M portfolio in Q3 2017.
  • Healthcare Value Capital opened 3 new positions and closed 7 in Q3 2017.
  • Healthcare Value Capital's portfolio value fell 10% quarter-over-quarter to $50M.

Based on Healthcare Value Capital's 13F filing for Q3 2017, filed 13 Nov 2017.